Clinical trials: Blindness
Hemianopia, Homonymous, Hemianopsia, Homonymous
VR System for Cross-modal Rehabilitation of Hemianopia
The purpose of this research study is to investigate the effectiveness of a new rehabilitation for visual hemianopia. The study team believes a cross-modal rehabilitation technique delivered by a virtual reality system can help…
- Trial name
- NCT04230486
- Testing
- Cross-model Visual Auditory Rehabilitation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Wake Forest University Health Sciences
Homonymous Hemianopia, Homonymous Quadrantanopia
Reminder-cue Scanning Training for Homonymous Visual Field Loss
This study will evaluate a new approach to training people with visual field loss to scan when driving
- Trial name
- NCT06136169
- Testing
- Reminder-cue scanning training
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Stroke Induced Vision Loss, Hemianopia
Visual Restoration for Hemianopia
The purpose of this research is to assess the efficacy of a visual training task on reducing the size of a visual field deficit caused by brain damage in adults, and its ability to improve visual functions in this patient…
- Conditions
- Stroke Induced Vision Loss, Hemianopia, Quadrantanopia
- Trial name
- NCT03350919
- Testing
- Training in the blind field, Training in the intact field
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- University of Rochester
Blindness
Emergency Egress and Information System for Persons With Vision Loss
The purpose of the research project is to develop and evaluate an emergency egress system for persons with visual impairment, which would use existing lighted exit signage to provide egress information at a distance of up to 100…
- Trial name
- NCT00262509
- Testing
- Egress Badge
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Diabetic Macular Edema, Diabetic Retinopathy
ADVM-022 Intravitreal Gene Therapy for DME
A Phase 2, Multi-Center, Randomized, Double-Masked*, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects with Diabetic Macular Edema [INFINITY]
- Trial name
- INFINITY (NCT04418427)
- Testing
- 6E11 vg/eye of ADVM-022, 2E11 vg/eye of ADVM-022, Aflibercept
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 36 people
- Sponsor
- Adverum Biotechnologies, Inc.
Blindness, Spinal Cord Injury
Use of "Smart Wheelchairs" to Provide Independent Mobility to Visual and Mobility Impairments
The goal of this project is to evaluate the Smart Wheelchair Component System (SWCS) for power wheelchairs and the Smart Power Assistance Module (SPAM) for manual wheelchairs in realistic indoor environments with target users…
- Trial name
- NCT00333762
- Testing
- Smart Power Assistance Module (SPAM), Smart Wheelchair Component System (SWCS)
- Where
- 2 sites in United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Usher Syndrome, Retinitis Pigmentosa
Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B
To evaluate the safety and tolerability of ascending doses of subretinal injections of SAR421869 in participants with Usher syndrome type 1B. To evaluate for possible biological activity of SAR421869.
- Trial name
- NCT01505062
- Testing
- SAR421869
- Where
- 2 sites in United States, France
- Volunteers
- 9 people
- Sponsor
- Sanofi
Retinitis Pigmentosa, Usher Syndrome Type 2
Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
The purpose of this study is to evaluate the efficacy safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene.
- Conditions
- Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease
- Trial name
- NCT05158296
- Testing
- Ultevursen
- Where
- 15 sites in United States, Germany and 2 more
- Volunteers
- 7 people
- Sponsor
- Laboratoires Thea
Acute Stroke, Visual Field Loss
Fluoxetine for Visual Recovery After Ischemic Stroke
The purpose of this study is to determine whether fluoxetine, a selective serotonin reuptake inhibitor commonly used for depression, enhances visual recovery after an acute ischemic stroke.
- Trial name
- FLUORESCE (NCT02737930)
- Testing
- Fluoxetine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Bogachan Sahin
Homonymous Hemianopia
Clinical Trial of Multi-Periscopic Prism Glasses for Hemianopia
This clinical trial will evaluate the efficacy of two types of high-power prism glasses that provide field of view expansion for patients with homonymous hemianopia (the complete loss of half the field of vision on the same side…
- Trial name
- NCT04827147
- Testing
- Multi-Periscopic Prism (MPP) glasses, Fresnel Peripheral Prism (FPP) glasses
- Where
- 8 sites in United States
- Volunteers
- 64 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
One Eye Blindness, Blind Left Eye
Multiplexing Prism Fitting for Field Expansion of Monocular Vision
The investigators are developing an assistive device, known as multiplexing prism that expands the field of view for individuals with acquired monocular vision (loss of an eye).
- Conditions
- One Eye Blindness, Blind Left Eye, Blind Right Eye
- Trial name
- NCT06027216
- Testing
- Multiplexing Prism
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Macular Degeneration
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)
This study is a phase III, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration.
- Trial name
- VIEW 2 (NCT00637377)
- Testing
- Ranibizumab, Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
- Where
- 189 sites in Argentina, Australia and 24 more
- Volunteers
- 1,240 people
- Sponsor
- Bayer
Scotoma, Central, Central Visual Impairment
Visuomotor Rehabilitation Training for Manual Task Deficits From Macular Scotomas
The research is aimed at developing and testing a new method of visual-motor rehabilitation of Veterans with macular degeneration by using inexpensive "tablet" computers at home.
- Trial name
- VRT (NCT01691027)
- Testing
- Visuo-motor training
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- VA Office of Research and Development
Retinitis Pigmentosa, Usher Syndrome Type 2
Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa
This clinical trial is a single-site, 30 patient study for participants who have early stage retinitis pigmentosa, or Usher syndrome (type 2 or 3). Funding Source - FDA OOPD and Foundation Fighting Blindness.
- Conditions
- Retinitis Pigmentosa, Usher Syndrome Type 2, Usher Syndrome Type 3
- Trial name
- NCT01530659
- Testing
- NT-501
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Neurotech Pharmaceuticals
Insomnia, Blindness
Melatonin for Circadian Sleep Disorders in the Blind
This research project consists of a three part study with five embedded sub studies. The first study phase identifies "body rhythms" of sleepiness/wakefulness and of melatonin levels for each subject (including sub-study 1).
- Conditions
- Insomnia, Blindness, Daytime Sleepiness
- Trial name
- NCT00911053
- Testing
- Melatonin, Regular Sleep Schedule, Light
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Oregon Health and Science University
Macular Degeneration, Central Visual Impairment
Scotoma Perimetry Oculomotor Training
The proposed research is relevant to public health because a greater understanding of plasticity after central vision loss can inform new therapies for treating low vision and has potential to benefit millions of individuals…
- Trial name
- SPOT (NCT05456581)
- Testing
- 'Scotoma awareness' Training, Control Training
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Alabama at Birmingham
Age Related Macular Degeneration, Retinitis Pigmentosa
Visual Activity Evoked by Infrared in Humans After Dark Adaptation
This pilot study will evaluate the visual response to infrared (IR) in humans after dark adaptation. The investigators plan to determine which wavelength and intensity the human eye is most sensitive to in healthy and color-blind…
- Conditions
- Age Related Macular Degeneration, Retinitis Pigmentosa, Congenital Stationary Night Blindness, Colorblindness
- Trial name
- NCT02909985
- Testing
- Tungsten halogen light with narrow bandpass filters
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of New Mexico
Carotid Artery Disease, Stroke
Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy
The objective of the CANOPY trial is to assess the continued safety and effectiveness of the RX Acculink Carotid Stent System under commercial use in subjects at standard risk for adverse events from Carotid Endarterectomy (CEA)…
- Conditions
- Carotid Artery Disease, Stroke, Amaurosis Fugax, Transient Ischemic Attack (TIA)
- Trial name
- CANOPY (NCT01445613)
- Testing
- RX Acculink Carotid Stent System (RX Acculink)
- Where
- United States
- Volunteers
- 1,203 people
- Sponsor
- Abbott Medical Devices
Deafness, Blindness
Workshops for Veterans With Vision and Hearing Loss
This is a pilot study of workshops to help Veterans with both vision and hearing loss live a happier, fuller and less stressful life. The results will be used to guide the development of a large scale clinical trial.
- Trial name
- DSLW (NCT01109576)
- Testing
- DSL Workshop
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- US Department of Veterans Affairs
Macular Degeneration, Wet Macular Degeneration
Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration
The purpose of the current study is to evaluate the ability of Eylea to induce a regression of PED height on patients previously extensively treated by Lucentis.
- Conditions
- Macular Degeneration, Wet Macular Degeneration, Retinal Degeneration, Retinal Diseases
- Trial name
- ARI2 (NCT02157077)
- Testing
- Aflibercept
- Where
- 9 sites in France
- Volunteers
- 84 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil